

Approved



**Angola**  
**Country Operational Plan**  
**FY 2016**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		27,052		27,052	0	27,052
USAID		4,459,425	4,400,000	8,859,425	500,000	9,359,425
DOD		1,472,527		1,472,527	263,725	1,736,252
HHS/CDC	401,250	4,976,021		5,377,271	1,200,000	6,577,271
<b>Total</b>	<b>401,250</b>	<b>10,935,025</b>	<b>4,400,000</b>	<b>15,736,275</b>	<b>1,963,725</b>	<b>17,700,000</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency				On Hold Amount	Total
	State	DOD	HHS/CDC	USAID		
HBHC		233,258	240,823	325,833	0	799,914
HLAB		85,727	322,209		0	407,936
HTXS		204,125	799,471	1,328,109	0	2,331,705
HVCT		626,052	191,867	1,578,180	0	2,396,099
HVMS	27,052	74,460	1,613,944	768,734	0	2,484,190
HVOP		197,995		1,479,996	0	1,677,991
HVSI			1,034,690	619,889	0	1,654,579
HVTB			387,529		0	387,529
OHSS		50,910	289,686	2,220,721	0	2,561,317
PDCS			64,436	64,436	0	128,872
PDTX			432,616	473,527	0	906,143
	<b>27,052</b>	<b>1,472,527</b>	<b>5,377,271</b>	<b>8,859,425</b>	<b>0</b>	<b>15,736,275</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	710,207	0
HVTB	350,000	0
PDCS	128,872	0
<b>Total Technical Area Planned Funding:</b>	<b>1,189,079</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	346,895	0
HVSI	1,429,893	0
OHSS	2,220,360	0
<b>Total Technical Area Planned Funding:</b>	<b>3,997,148</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HVCT	2,281,597	0
HVOP	1,465,638	0
<b>Total Technical Area Planned Funding:</b>	<b>3,747,235</b>	<b>0</b>

#### Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	2,158,648	0
PDTX	906,143	0

Approved



<b>Total Technical Area Planned Funding:</b>	<b>3,064,791</b>	<b>0</b>
--	------------------	----------



### Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	21,576
	Total number of people in the target population	100,000
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	20,497
	Aggregated Age/sex: <15 Female	
Aggregated Age/sex: 15+ Female	1,079	
KP_PREV_TA	KP_PREV_TA Percentage of key	n/a



	<p>populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)</p>	
	<p>Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required</p>	<p>16,500</p>
	<p>Total estimated number of key population in the catchment area</p>	<p>33,250</p>
	<p>By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>10,000</p>
	<p>By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are</p>	



	based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	19,290
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	6,500
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual	



	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men and are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	13,960
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual	



	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known positive	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: Returning beneficiary within the current report period	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	96,003
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	



	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex:	



	Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,738
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	43,956
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,756
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	43,873
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	450
	Test Result by Aggregated Age and Sex: Positive 15+ Male	3,354
	Test Result by Aggregated Age and Sex: Positive <15 Female	502
	Test Result by Aggregated Age	4,862



	and Sex: Positive 15+ Female	
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	1,351
	Service Delivery Point (Community): Other	13,231
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	1,010
	Service Delivery Point (Facility): Outpatient	3,718
	Service Delivery Point (Facility):	195



	Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	0
	Service Delivery Point (Facility): Other PITC	7,205
	Service Delivery Point (Facility): VCT	48,675
	Service Delivery Point (Facility): VMMC	0
	Service Delivery Point (Facility): PMTCT	8,708
	Service Delivery Point (Facility): TB Clinics	9,296
	Service Delivery Point (Facility): Index testing	2,614
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by	



	Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
	TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.
Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		8,820
Total number of registered new and relapsed TB cases, during the reporting period.		9,800
Age/Sex: <1 (Numerator: Number		



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the	



	reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	655
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,374
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	493



	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,298
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and	



	relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,111
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,588
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	



	the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	83
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	551
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	62
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	415
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	



	period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator:	



	<p>The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB</p>	



	cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	27,468
	Age/Sex: <1 Male	



	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	1,825
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	8,974
	Aggregated Age/Sex: <15 Female	1,918
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	14,751
	Sum of Aggregated Age/Sex <15	3,743
	Sum of Aggregated Age/Sex 15+	23,725
	Sum of Aggregated Age/Sex disaggregates	27,468
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	



	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8,397
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	551
Aggregated Grouping by Age/Sex: 1-14 Male		
Aggregated Grouping by Age/Sex: 15+ Male	2,717	



	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	612
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	4,517
	Sum of Aggregated Age/Sex disaggregates	8,397
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	10,950
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	15,000
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication:	



	1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication:	



	25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	9,308
	Numerator: Indication: Targeted	1,642
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication:	



	Pregnant Targeted	
	Denominator: Indication: Routine	12,747
	Denominator: Indication: Targeted	2,253
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by	



	Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by	



	Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	807
	Numerator Aggregated Age/Sex: 15+ Male	3,034
	Numerator Aggregated Age/Sex: <15 Female	853
	Numerator Aggregated Age/Sex: 15+ Female	6,256
	Denominator Aggregated Age/Sex: <15 Male	1,106
	Denominator Aggregated Age/Sex: 15+ Male	4,155
	Denominator Aggregated Age/Sex: <15 Female	1,167
	Denominator Aggregated Age/Sex: 15+ Female	8,572
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,725
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those	8,406



	who have died, those who have stopped ART, and those lost to follow-up	
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	



	initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of	



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	



	stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of	



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status:	



	Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	746
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,606
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,395
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,978
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	933
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	2,008



	those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,743
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,722
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
	CD4: Number of laboratories that participate in this PT program	9
	CD4: Number of laboratories that perform this testing	9
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	Early infant diagnostics: Number of	1



	laboratories that participate in this PT program	
	Early infant diagnostics: Number of laboratories that perform this testing	1
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	30
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	30
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	30
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
	HIV viral load: Number of laboratories that participate in this PT program	2
	HIV viral load: Number of laboratories that perform this testing	2
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	2
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	2



	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	4
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	4
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
13559	JHPIEGO	University	U.S. Agency for International Development	GHP-USAID	927,803
13607	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-USAID	0
17306	World Learning	NGO	U.S. Agency for International Development	GHP-State	0
17308	LINKAGES	NGO	U.S. Agency for International Development	GHP-State	2,222,878
17397	Charles Drew University	University	U.S. Department of Defense	GHP-State	1,312,252
17490	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	601,895
17848	Ministry of Health, Angola	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	790,000



17850	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,856,681
17851	Ministry of Health, Angola	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	150,000
18347	Population Services International	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	2,744,555
18348	ICF Macro	Private Contractor	U.S. Agency for International Development	GHP-USAID	125,000
18437	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-USAID	1,267,189



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 13559</b>	<b>Mechanism Name: Strengthening Angolan Systems for Health (SASH)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 927,803</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 927,803</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	927,803

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13559		
<b>Mechanism Name:</b>	Strengthening Angolan Systems for Health (SASH)		
<b>Prime Partner Name:</b>	JHPIEGO		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	24,720	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	PDCS	15,465	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	47,950	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	133,982	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	250,067	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	338,935	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	116,684	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2017
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	16,457
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	682
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,043
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	936
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,796



HTC_TST_TA	Sum of Aggregated Age/Sex <15	1,618
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	14,839
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	16,457
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	112
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	611
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	125
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,054
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	151
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	161
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	49
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	1,801
HTC_TST_TA	Service Delivery Point (Facility): VCT	9,259
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	2,178
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	2,205
HTC_TST_TA	Service Delivery Point (Facility): Index testing	653
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	9,002
TX_CURR_TA	Aggregated Age/Sex: <15 Male	646
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	2,509
TX_CURR_TA	Aggregated Age/Sex: <15 Female	675
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	5,172
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,321
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	7,681
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	9,002
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,937
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	137



TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	536
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	153
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	1,111
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	1,937
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	685
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	854
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	32
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	194
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	32
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	427
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	38
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	242
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	40



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	534

**Implementing Mechanism Details**

<b>Mechanism ID: 13607</b>	<b>Mechanism Name: SIAPS - OLD</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13607		
<b>Mechanism Name:</b>	SIAPS - OLD		
<b>Prime Partner Name:</b>	Management Sciences for Health		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Approved



Governance and Systems	OHSS	0	0
------------------------	------	---	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17306</b>	<b>Mechanism Name: Comité Empresarial Contra VIH/SIDA (CEC-HIV/AIDS)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Learning	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17306		
<b>Mechanism Name:</b>	Comité Empresarial Contra VIH/SIDA (CEC-HIV/AIDS)		
<b>Prime Partner Name:</b>	World Learning		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	OHSS	0	0
------------------------	------	---	---

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 17308</b>	<b>Mechanism Name: LINKAGES</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: LINKAGES	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,222,878</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,222,878</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,222,878

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17308		
<b>Mechanism Name:</b>	LINKAGES		
<b>Prime Partner Name:</b>	LINKAGES		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HBHC	177,593	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	143,093	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	138,957	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	484,865	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	1,278,370	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	16,500
KP_PREV_TA	Total estimated number of key population in the catchment area	33,250
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10,000
KP_PREV_TA	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	19,290



KP_PREV_TA	By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	6,500
KP_PREV_TA	By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	13,960
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	13,231
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,721
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	6,830
HTC_TST_TA	Sum of Aggregated Age/Sex <15	0
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	11,551
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	11,551
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	235
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	566
HTC_TST_TA	Service Delivery Point (Community): Other	13,231

### Implementing Mechanism Details

<b>Mechanism ID: 17397</b>	<b>Mechanism Name: CDU Angola</b>
----------------------------	-----------------------------------



Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Charles Drew University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,312,252</b>	
<b>Applied Pipeline Amount: 250,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,562,252</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,312,252

**Cross-Cutting Budget Attribution(s)**

Motor Vehicles: Purchased	66,078
---------------------------	--------

**Budget Code Information**

<b>Mechanism ID:</b> 17397			
<b>Mechanism Name:</b> CDU Angola			
<b>Prime Partner Name:</b> Charles Drew University			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	222,531	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	75,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	50,910	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	604,598	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	187,268	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	171,945	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	21,576
PP_PREV_TA	Total number of people in the target population	100,000
PP_PREV_TA	Aggregated Age/sex: 15+ Male	20,497
PP_PREV_TA	Aggregated Age/sex: 15+ Female	1,079
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	16,943
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	15,062
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	11
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,863
HTC_TST_TA	Sum of Aggregated Age/Sex <15	18
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	16,925
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	16,943



HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	674
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	83
HTC_TST_TA	Service Delivery Point (Community): Mobile testing	1,351
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	405
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	3,073
HTC_TST_TA	Service Delivery Point (Facility): VCT	11,691
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	422
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,051
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,897
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	154
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	2,051
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,051
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	644
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	573
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	71
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	644

**Implementing Mechanism Details**

<b>Mechanism ID: 17490</b>	<b>Mechanism Name: APHL</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 601,895</b>	
<b>Applied Pipeline Amount: 318,105</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 920,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>



GHP-State	601,895
-----------	---------

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	1
----------------------------	---

**Budget Code Information**

<b>Mechanism ID:</b> 17490			
<b>Mechanism Name:</b> APHL			
<b>Prime Partner Name:</b> Association of Public Health Laboratories			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	201,895	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	100,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2017
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
LAB_PT_TA	CD4: Number of laboratories that participate in this PT	9



	program	
LAB_PT_TA	CD4: Number of laboratories that perform this testing	9
LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	Early infant diagnostics: Number of laboratories that participate in this PT program	1
LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	1
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	30
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	30
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	30
LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	2
LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	2
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	2
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	2
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of	4



	laboratories that participate in this PT program	
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	4
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1

**Implementing Mechanism Details**

<b>Mechanism ID: 17848</b>	<b>Mechanism Name: INLS</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Angola	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 790,000</b>	
<b>Applied Pipeline Amount: 60,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 850,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	790,000

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	1
----------------------------	---

**Budget Code Information**

<b>Mechanism ID: 17848</b>
----------------------------



<b>Mechanism Name:</b> INLS			
<b>Prime Partner Name:</b> Ministry of Health, Angola			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	85,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	70,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	590,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	45,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17850	<b>Mechanism Name:</b> ICAP
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 1,856,681	
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 1,856,681	
Funding Source	Funding Amount
GHP-State	1,856,681



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17850			
<b>Mechanism Name:</b> ICAP			
<b>Prime Partner Name:</b> Columbia University Mailman School of Public Health			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	28,073	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	150,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	64,436	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	330,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	139,372	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	91,867	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	665,317	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	387,616	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,079
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	990
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,012
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,061
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	10,016
HTC_TST_TA	Sum of Aggregated Age/Sex <15	2,051
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	18,028
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	20,079
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	157
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,033
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	174
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,267
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	605
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	644
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	194
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0



HTC_TST_TA	Service Delivery Point (Facility): Other PITC	7,204
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	8,820
HTC_TST_TA	Service Delivery Point (Facility): Index testing	2,612
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	8,820
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	9,800
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	655
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,374
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	493
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,298
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,111
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,588
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	83
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	551
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with	62



	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	415
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	25,417
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,825
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	7,077
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,918
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	14,597
TX_CURR_TA	Sum of Aggregated Age/Sex <15	3,743
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	21,674
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	25,417
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	7,753
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	551
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	2,144
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	612
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	4,446
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	7,753
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	10,950
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	15,000
TX_PVLS_TA	Numerator: Indication: Routine	9,308
TX_PVLS_TA	Numerator: Indication: Targeted	1,642
TX_PVLS_TA	Denominator: Indication: Routine	12,747
TX_PVLS_TA	Denominator: Indication: Targeted	2,253



TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	807
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	3,034
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	853
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	6,256
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	1,106
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	4,155
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	1,167
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	8,572
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,725
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,406
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	746
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,606
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,395
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,978
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	933
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	2,008



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,743
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,722

**Implementing Mechanism Details**

<b>Mechanism ID: 17851</b>	<b>Mechanism Name: SPH</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Angola	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 150,000</b>	
<b>Applied Pipeline Amount: 50,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 200,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	150,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**



<b>Mechanism ID: 17851</b>			
<b>Mechanism Name: SPH</b>			
<b>Prime Partner Name: Ministry of Health, Angola</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	50,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	100,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18347</b>	<b>Mechanism Name: Health for All (HFA)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,744,555</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,744,555</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,236,547
GHP-USAID	508,008

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 18347			
<b>Mechanism Name:</b> Health for All (HFA)			
<b>Prime Partner Name:</b> Population Services International			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	72,290	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	48,971	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	143,850	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	389,950	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	750,200	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	982,451	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	356,843	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2017
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	49,372
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,049
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	18,130
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,809
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	26,384
HTC_TST_TA	Sum of Aggregated Age/Sex <15	4,858
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	44,514
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	49,372
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	338
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,834
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	377
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,159
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	454
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	484
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	146
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	5,404
HTC_TST_TA	Service Delivery Point (Facility): VCT	27,725
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	6,530
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	6,669
HTC_TST_TA	Service Delivery Point (Facility): Index testing	1,960



TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	25,417
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,825
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	7,077
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,918
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	14,597
TX_CURR_TA	Sum of Aggregated Age/Sex <15	3,743
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	21,674
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	25,417
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,816
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	414
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	1,608
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	459
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	3,335
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	5,816
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	10,950
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	15,000
TX_PVLS_TA	Numerator: Indication: Routine	9,308
TX_PVLS_TA	Numerator: Indication: Targeted	1,642
TX_PVLS_TA	Denominator: Indication: Routine	12,747
TX_PVLS_TA	Denominator: Indication: Targeted	2,253
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	807
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	3,034
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	853
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	6,256
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	1,106
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	4,155



TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	1,167
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	8,572
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,725
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,406
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	746
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,606
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,395
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,978
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	933
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,008
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,743



TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,722
-----------	---	-------

### Implementing Mechanism Details

<b>Mechanism ID: 18348</b>	<b>Mechanism Name: DHS 7</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: ICF Macro	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 125,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 125,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	125,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 18348			
<b>Mechanism Name:</b> DHS 7			
<b>Prime Partner Name:</b> ICF Macro			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	125,000	0



### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18437</b>	<b>Mechanism Name: Procurement and Supply Management (PSM)</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Chemonics International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:
<b>Total All Funding Sources: 1,267,189</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,267,189</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	1,267,189

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18437		
<b>Mechanism Name:</b>	Procurement and Supply Management (PSM)		
<b>Prime Partner Name:</b>	Chemonics International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	OHSS	1,267,189	0



Systems			
---------	--	--	--

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	25,417
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,825
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	7,077
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,918
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	14,597
TX_CURR_TA	Sum of Aggregated Age/Sex <15	3,743
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	21,674
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	25,417
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	7,753
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	551
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	2,144
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	612
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	4,446
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	7,753

### Agency Information - Costs of Doing Business

#### U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT			50,000	0	50,000	50,000



Services						
ICASS			137,000	0	137,000	137,000
Non-ICASS Administrative Costs			305,000	0	305,000	305,000
Staff Program Travel			160,000	20,000	160,000	180,000
USG Staff Salaries and Benefits - Locally Recruited			920,000	480,000	920,000	1,400,000
<b>Total</b>	<b>0</b>	<b>0</b>	<b>1,572,000</b>	<b>500,000</b>	<b>1,572,000</b>	<b>2,072,000</b>

**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
ICASS		40,000		0	40,000	40,000
Institutional Contractors				0	0	0
Management Meetings/Profes sional Development		5,000		0	5,000	5,000
Non-ICASS Motor Vehicles		7,000		0	7,000	7,000
Peace Corps				0	0	0



Volunteer Costs						
Staff Program Travel		41,275		13,725	41,275	55,000
USG Staff Salaries and Benefits - Internationally Recruited				0	0	0
USG Staff Salaries and Benefits - Locally Recruited		67,000		0	67,000	67,000
<b>Total</b>	<b>0</b>	<b>160,275</b>	<b>0</b>	<b>13,725</b>	<b>160,275</b>	<b>174,000</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing	179,687			0	179,687	179,687
Computers/IT Services		30,000		0	30,000	30,000
ICASS	221,563	778,437		0	1,000,000	1,000,000
Management Meetings/Professional		97,137		0	97,137	97,137



Development						
Non-ICASS Administrative Costs		45,000		0	45,000	45,000
Staff Program Travel		10,000		35,000	10,000	45,000
USG Staff Salaries and Benefits - Internationally Recruited		264,625		556,895	264,625	821,520
USG Staff Salaries and Benefits - Locally Recruited		352,246		180,000	352,246	532,246
<b>Total</b>	<b>401,250</b>	<b>1,577,445</b>	<b>0</b>	<b>771,895</b>	<b>1,978,695</b>	<b>2,750,590</b>

**U.S. Department of State**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Management Meetings/Professional Development		27,052		0	27,052	27,052
<b>Total</b>	<b>0</b>	<b>27,052</b>	<b>0</b>	<b>0</b>	<b>27,052</b>	<b>27,052</b>

Approved

